ARS Pharmaceuticals, Inc. Operating Income (Loss) in USD from Q1 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ARS Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q3 2025.
  • ARS Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$53.2M, a 145% decline year-over-year.
  • ARS Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$90.8M, a 50% decline year-over-year.
  • ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$3.08M, a 95.4% increase from 2023.
  • ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$67.5M, a 90.1% decline from 2022.
  • ARS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$35.5M, a 82.6% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

ARS Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$90.8M -$53.2M -$31.4M -145% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$59.3M -$47.6M -$32.3M -210% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 -$27.1M -$37.2M -$24M -182% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 -$3.08M $47.2M +$57.4M Oct 1, 2024 Dec 31, 2024 10-K 2025-03-20
Q3 2024 -$60.5M -$21.7M -$3.77M -21% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 -$56.7M -$15.3M +$5.26M +25.5% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 -$62M -$13.2M +$5.52M +29.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 -$67.5M -$10.2M +$5.22M +33.8% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-20
Q3 2023 -$72.7M -$18M -$11.3M -171% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$61.4M -$20.6M -$14.3M -225% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$47.1M -$18.7M -$11.6M -164% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$35.5M -$15.4M -$62.1M -133% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $26.6M -$6.63M +$16.1M +70.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $10.5M -$6.34M +$18.2M +74.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$7.67M -$7.1M +$11.8M +62.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$19.5M $46.6M +$59.7M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$79.2M -$22.7M -$14.6M -180% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$64.6M -$24.5M -$18M -279% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$46.6M -$18.9M -$13.6M -260% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$32.9M -$13.1M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$8.11M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$6.46M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$5.24M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13

ARS Pharmaceuticals, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$3.08M +$64.4M +95.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-20
2023 -$67.5M -$32M -90.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-20
2022 -$35.5M -$16.1M -82.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$19.5M +$13.5M +40.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-23
2020 -$32.9M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.